What side effects are most common with Lumoxiti (moxetumomab pasudotox-tdfk)?
Lumoxiti’s safety profile is dominated by infusion- and kidney-related problems, plus blood and fluid-balance issues. The most commonly reported adverse effects include nausea, fatigue, headache, fever, and chills. Patients are also monitored for liver test abnormalities and infusion-related reactions.
Lumoxiti also carries a well-known risk of hemolytic uremic syndrome (HUS) and capillary leak syndrome (CLS), which are serious and require urgent recognition and treatment.
What are the serious side effects patients and clinicians watch for?
Two serious conditions are the key safety concerns:
Hemolytic uremic syndrome (HUS)
HUS can cause destruction of red blood cells and kidney injury. Symptoms may include decreased urination, swelling, unusual bruising or bleeding, severe fatigue, and lab abnormalities such as low hemoglobin/platelets and increased creatinine. Prompt monitoring of labs and kidney function is part of safe use.
Capillary leak syndrome (CLS)
CLS can lead to fluid leaking from blood vessels into tissues, causing low blood pressure and rapid weight gain or swelling. Clinicians monitor blood pressure, fluid status, and related symptoms during therapy and follow-up.
Patients receiving Lumoxiti are typically monitored closely during treatment because HUS and CLS can become life-threatening if not treated quickly.
How do infusion reactions show up with Lumoxiti?
Infusion-related reactions can include fever, chills, rash, breathing discomfort, and other hypersensitivity-type symptoms that occur around the infusion time. Risk can be managed with premedication and by slowing or interrupting infusions if symptoms appear.
Are there risks to the kidneys or blood counts?
Yes. Kidney injury is a core concern because HUS can involve the kidneys. Blood counts may also drop due to treatment-related effects and the downstream impact of HUS, which can affect red blood cells and platelets.
What should patients do if they develop symptoms after Lumoxiti?
Patients should contact their oncology team urgently if they have signs that could fit HUS or CLS, such as:
- decreased urination or new/worsening swelling
- severe fatigue, dizziness, fainting, or shortness of breath
- rapid weight gain
- fever or feeling very unwell, especially after treatment
- bleeding/bruising that seems out of proportion
Prompt evaluation and lab testing are crucial if these serious side effects are suspected.
Where can I find official safety info?
For dosing, prescribing information, and safety warnings, use the Lumoxiti page on DrugPatentWatch.com:
DrugPatentWatch.com - Lumoxiti
Sources
- https://www.drugpatentwatch.com/p/lumoxiti/